Professional Tax Research Solutions from the Founder of Kleinrock. tax and accounting research
Parker Tax Pro Library
Accounting News Tax Analysts professional tax research software Like us on Facebook Follow us on Twitter View our profile on LinkedIn Find us on Pinterest
federal tax research
Professional Tax Software
tax and accounting
Tax Research Articles Tax Research Parker's Tax Research Articles Accounting Research CPA Client Letters Tax Research Software Client Testimonials Tax Research Software Federal Tax Research tax research

Accounting Software for Accountants, CPA, Bookeepers, and Enrolled Agents

CPA Tax Software



Doctor's Royalty Income from Patent Is Ordinary Income, Not Capital Gain

(Parker Tax Publishing April 2018)

The Third Circuit affirmed a Tax Court ruling that a doctor's royalty income from a patent that he received under a licensing agreement was ordinary income, not capital gains, because by retaining the right to decide how the technology was used, the doctor had failed to transfer substantially all rights to the patent. The Third Circuit also found that the doctor's argument on appeal was waived because it depended on a different legal theory and different facts than the argument he made before the Tax Court. Spireas v. Comm'r, 2018 PTC 83 (3d Cir. 2018).


Spiridon Spireas is a pharmaceutical scientist who invented "liquisolid technology," a set of drug delivery techniques meant to facilitate the body's absorption of water-insoluble molecules taken orally. The technology is not one-size-fits-all. Each application is specific to a particular drug, and creating a clinically useful liquisolid formulation of a given drug requires creating, through trial and error, a process specific to the substance involved.

Because each formulation was unique, commercializing the technology was complex process. Before a drug could go to market in liquisolid form, a specific formulation had to progress from conception to prototyping to extensive further development. Like many inventors, Spireas could not develop the technology alone, so in June 1998 he signed a licensing agreement with Mutual Pharmaceutical Co., an established drugmaker.

Spireas's agreement with Mutual established a comprehensive framework for licensing liquisolid technology to Mutual, selecting prescription drugs to develop, developing and selling those drugs, and paying Spireas royalties out of the proceeds. Mutual received exclusive rights to use the technology, but only to develop liquisolid drug products that were unanimously selected by written agreement between Mutual and Spireas. The parties memorialized their selections of which products to develop in formal engagement letters. Once an agreement was made, the process continued with the development of a practical liquisolid formulation, clinical testing, FDA approval, and marketing. As sales were made and funds were received, Mutual would pay Spireas a 20 percent royalty on the gross profits.

In March 2000, Spireas and Mutual signed an engagement letter to develop a generic version of a blood pressure drug called felodipine. Spireas put forth considerable efforts to adapt the technology to felodipine and completed his efforts in a relatively short amount of time. When he signed the engagement letter, he had completed roughly 30 percent of the work that ultimately resulted in the liquisolid formulation of felodipine that he finished inventing sometime after May 2000. The FDA approved felodipine and Mutual marketed it to great success.

Spireas's royalties for 2007-2008, the years at issue, totaled just over $40 million, which he reported as capital gains on his tax returns. In 2013, the IRS sent a notice of deficiency stating that the royalties were ordinary income, and it assessed around $5.8 million in additional tax. Spireas petitioned the Tax Court for a redetermination.


Royalty payments received under a license agreement are generally taxed as ordinary income. However, Code Sec. 1235(a) provides a transfer of all substantial rights to a patent is treated as a sale or exchange of a capital asset held for more than one year. Under Reg. Sec. 1.1235-2(b)(1), "all substantial rights" means all rights to a patent which are of value at the time the rights are transferred.

An inventor must transfer property rights that the inventor actually possesses at the time of the grant, and to possess a transferable property interest the inventor generally must have reduced it to actual practice. Under Reg. Sec. 1.1235-2(e), an invention is reduced to actual practice when it has been tested and operated successfully under normal operating conditions.

Before the Tax Court, the IRS argued that Spireas failed transfer all of his rights to liquisolid technology as required under Code Sec. 1235 because Mutual could only sell those products that it and Spireas unanimously selected. Spireas acknowledged that he had retained valuable rights in the overall technology but emphasized that he had transferred away all of his rights to the liquisolid formulation of felodipine, and that the transfer took place sometime in 2000 or 2001, after the felodipine formulation was invented.

The Tax Court agreed with the IRS, finding that Spireas could not have transferred the rights to any particular liquisolid products in 1998 because no products existed at that time. According to the Tax Court, the only rights Spireas could have granted in 1998 were the rights to use the liquisolid technology and to make and sell any products using the technology. The Tax Court held that, since Spireas had granted far less than all substantial rights to the overall liquisolid technology, the royalty payments he received in 2007 and 2008 did not satisfy the requirements of Code Sec. 1235 and were therefore taxable as ordinary income.

Spireas appealed to the Third Circuit. On appeal, he argued that the transfer of his rights occurred in 1998 with the execution of the licensing agreement, which he claimed prospectively assigned to Mutual his rights to liquisolid felodipine. The IRS responded that Spireas had waived that argument by not presenting it to the Tax Court. The IRS claimed that under Third Circuit precedent, Spireas's argument on appeal had to be based on the same legal rule and facts as the argument he made before the Tax Court, and that his new argument failed this test.

The Third Circuit affirmed the Tax Court and held that Spireas had waived his argument that he prospectively transferred the rights. The court explained that the under the waiver rule, Spireas's argument on appeal had to depend on the same legal rule and the same material facts as the argument he presented to the Tax Court.

The Third Circuit found the legal theory Spireas presented to the Tax Court was that he acquired a property interest in liquisolid felodipine when the invention was complete, either in 2000 or 2001. In the Third Circuit's view, that determination implied a finding by the Tax Court that the formulation had been reduced to actual practice at that time. Thus, the Third Circuit found that Spireas's original theory was that he made a post-invention transfer of his rights to Mutual around May 2000, which is the time that he acquired a property interest in the invention.

The Third Circuit found that Spireas abandoned that theory on appeal, and instead had argued that he prospectively transferred his rights in 1998, two years before the invention of liquisolid felodipine. According to the Third Circuit, Spireas's argument for a prospective transfer could not depend on a theory of "actual reduction to practice" because it depended on a different legal standard for when the formulation became property than his argument to the Tax Court. The Third Circuit also reasoned that the prospective transfer could not depend on the same facts (including the timing of felodipine's invention) as those supporting his Tax Court argument.

For these reasons, and because Spireas offered no reasons why the court should excuse his waiver, the Third Circuit declined to evaluate his new argument on appeal and affirmed the Tax Court's decision.

Observation: In a dissenting opinion, one judge would have held that Spireas's arguments before the Tax Court and on appeal were consistent. In the view of the dissenting judge, Spireas consistently argued that the physical delivery of the formulation occurred in 2000 pursuant to the 1998 transfer of the legal rights to the formulation, and that such rights were the consideration for the royalty payments Spireas received. The dissent also disagreed with the majority's view that an invention must be reduced to practice in order for Code Sec. 1235 to apply, and reasoned that by the logic of the majority opinion, the 2000 engagement letter could not have transferred the rights because it also predated the felodipine formulation's reduction to practice.

For a discussion of the taxation of gain or loss from the transfer of patents, see Parker Tax ¶117,110.

Disclaimer: This publication does not, and is not intended to, provide legal, tax or accounting advice, and readers should consult their tax advisors concerning the application of tax laws to their particular situations. This analysis is not tax advice and is not intended or written to be used, and cannot be used, for purposes of avoiding tax penalties that may be imposed on any taxpayer. The information contained herein is general in nature and based on authorities that are subject to change. Parker Tax Publishing guarantees neither the accuracy nor completeness of any information and is not responsible for any errors or omissions, or for results obtained by others as a result of reliance upon such information. Parker Tax Publishing assumes no obligation to inform the reader of any changes in tax laws or other factors that could affect information contained herein.

Parker Tax Pro Library - An Affordable Professional Tax Research Solution.

Professional tax research

We hope you find our professional tax research articles comprehensive and informative. Parker Tax Pro Library gives you unlimited online access all of our past Biweekly Tax Bulletins, 22 volumes of expert analysis, 250 Client Letters, Bob Jennings Practice Aids, time saving election statements and our comprehensive, fully updated primary source library.

Parker Tax Research

Try Our Easy, Powerful Search Engine

A Professional Tax Research Solution that gives you instant access to 22 volumes of expert analysis and 185,000 authoritative source documents. But having access won’t help if you can’t quickly and easily find the materials that answer your questions. That’s where Parker’s search engine – and it’s uncanny knack for finding the right documents – comes into play

Things that take half a dozen steps in other products take two steps in ours. Search results come up instantly and browsing them is a cinch. So is linking from Parker’s analysis to practice aids and cited primary source documents. Parker’s powerful, user-friendly search engine ensures that you quickly find what you need every time you visit Our Tax Research Library.

Parker Tax Research Library

Dear Tax Professional,

My name is James Levey, and a few years back I founded a company named Kleinrock Publishing. I started Kleinrock out of frustration with the prohibitively high prices and difficult search engines of BNA, CCH, and RIA tax research products ... kind of reminiscent of the situation practitioners face today.

Now that Kleinrock has disappeared into CCH, prices are soaring again and ease-of-use has fallen by the wayside. The needs of smaller firms and sole practitioners are simply not being met.

To address the problem, I’ve partnered with a group of highly talented tax writers to create Parker Tax Publishing ... a company dedicated to the idea that comprehensive, authoritative tax information service can be both easy-to-use and highly affordable.

Our product, the Parker Tax Pro Library, is breathtaking in its scope. Check out the contents listing to the left to get a sense of all the valuable material you'll have access to when you subscribe.

Or better yet, take a minute to sign yourself up for a free trial, so you can experience first-hand just how easy it is to get results with the Pro Library!


James Levey

Parker Tax Pro Library - An Affordable Professional Tax Research Solution.

    ®2012-2018 Parker Tax Publishing. Use of content subject to Website Terms and Conditions.

IRS Codes and Regs
Tax Court Cases IRS guidance